Russ Belden Bridge Consulting

Greetings CEO, The biotech sector downturn has been the longest in 36 years, nearly three years, but there's good news on the horizon. Interest rate cuts by the Federal Reserve and others signal an opportunity for investors to re-enter the biotech sector. Is your company ready for this change? For Phase III companies looking to fast-track commercialization build-out, Bridge can help you get there quickly and cost-effectively. With a focus on developing the Commercial & Medical Affairs "basecamp," including the "Commercialization Roadmap" and establishing Medical Affairs, we can assist in initiating critical commercial imperatives for success. I'm Russ Belden, Founder & CEO of Bridge, with a wealth of 36 years of biotech commercialization expertise, including work at Genentech and 120 other companies. If your company lacks the right Commercial leadership, or you need guidance on successful commercialization, reach out to me. Let's pave the way for your company's commercial success. Russ Belden Bridge: Founder & CEO russ@bridge1.net www.bridge1.net 415-307-0774 Danville, CA #commercialization #PhaseIII #biotech #pharma #CEO #medicalaffairs #PhaseIII #emergingbiotech

Today is World Cancer Research Day 2024! The theme is, “Innovation In Cancer Research Drives Progress Toward Health Equity.” The focus is on the need for breakthroughs across all stages of cancer care, from prevention to treatment. We celebrate the exciting breakthroughs in cancer detection and innovative treatments. How can you ensure the products of this research makes it to the bedside? I help emerging biotechs develop a Commercial and Medical Affairs "basecamp" including foundational investments in building a "Commercialization Roadmap" (36 months prelaunch and launch year), establishing Medical Affairs, and initiating critical long timeline commercial imperatives. Contact me to learn more. Russ Belden, russ@bridge1.net, 415-307-0774 www.bridge1.net #worldcancerresearchday #emergingbiotech #biotech #commercialization #gotomarket #medicalaffairs

Are you are a Phase III company and haven’t begun full scale commercialization build out? We can get you there – quickly and cost effectively. As a Phase III company, the commercialization focus should be on developing the Commercial & Medical Affairs “basecamp” including foundational investments in developing the “Commercialization Roadmap” (36 months prelaunch & launch year), establishing Medical Affairs, and initiating critical long timeline commercial imperatives. I'm Russ Belden, the founder & CEO of Bridge. If you don’t have the right Commercial leadership in place, are uncertain of your commercialization alternatives or, what it takes to commercialize successfully, give me a call and we’ll get your company on the path to commercial success. Russ Belden Bridge: Founder & CEO russ@bridge1.net www.bridge1.net 415-307-0774 Danville, CA At Bridge, we leverage our 36 years of biotech commercialization expertise from the early days at Genentech and 120 companies thereafter in providing the right level of commercial leadership at the right time. Our mission is making 1st time biotech CEO’s shine in the transition to a commercial company. #commercialization #PhaseIII #biotech #pharma #CEO #emergingbiotech #medicalaffairs

Sharing an interesting article on the #biotech sector from Nature Magazine. The headline, "After a difficult three years, biotech financing may slowly be returning to health." This is encouraging news. Interest rates now appear to be flat and trending downward, good news for biotech. This is an indicator that money may begin to flow again for emerging biotechs. In addition, "Selected VC's are in fact raising new funds. Assuming VC fundraising continues at this rate for the rest of the year, 2024 would see $20 billion in new biotech-focused funds, according to investment bank Stifel. That’s below 2021’s peaky $31 billion, but still a substantial step up from the previous decade." If you are a Phase III company and haven’t begun full scale commercialization build out at this point, we can get you there – quickly and cost effectively. Is your company positioned for the change? As a Phase III company, the commercialization focus should be on developing the Commercial & Medical Affairs “basecamp” including foundational investments in developing the “Commercialization Roadmap” (36 months prelaunch & launch year), establishing Medical Affairs, and initiating critical long timeline commercial imperatives. I'm Russ Belden, the founder & CEO of Bridge. If you don’t have the right Commercial leadership in place, are uncertain of your commercialization alternatives or, what it takes to commercialize successfully, give me a call and we’ll get your company on the path to commercial success. Russ Belden Bridge: Founder & CEO russ@bridge1.net www.bridge1.net 415-307-0774 Danville, CA https://lnkd.in/gz9DCVdP #commercialization #PhaseIII #biotech #pharma #CEO #medicalaffairs #biotechfunding #emergingbiotech

September is Ovarian Cancer Awareness Month. Ovarian cancer is often found in the later stages because the symptoms are very non-specific or there are no symptoms at all. This article highlights the 5 top global Pharma startups that are developing innovative treatments for ovarian cancer. They are: Tradewind BioScience, CEO Thaddeus Allen, antibody therapeutic for ovarian cancer. Adcendo, CEO Michael Pehl, antibody drug conjugates (ADCs). Enara Bio, CEO Andrew Fadden, targeted cancer immunotherapies. BioEclipse Therapeutics, Inc, CEO Pamela Contag, immuno-oncology therapeutics. BioVaxys Technology Corp., CEO James Passin, tumor cell vaccine. And one final mention - Genelux, CEO Thomas Zindrick, oncolytic immunotherapy. These companies are bringing hope to patients worldwide. #ovariancancer #immunotherapy #oncolytictherapy #immunooncology #vaccines

Greetings CEO,   The bad news is that this downturn in the biotech sector financing has been the longest in my 36 years in biotech - almost three years by this fall.    The good news is that interest rate cuts by the Federal Reserve in late September with others following through year end will send an “all clear” message to specialty and generalist investors to pile back into the biotech sector. Money will start to flow again.   Is your company positioned for the change? If you are a Phase III company and haven’t begun full scale commercialization build out at this point, we can get you there – quickly and cost effectively.    As a Phase III company, the commercialization focus should be on developing the Commercial & Medical Affairs “basecamp” including foundational investments in developing the “Commercialization Roadmap” (36 months prelaunch & launch year), establishing Medical Affairs, and initiating critical long timeline commercial imperatives.   I'm Russ Belden, the founder & CEO of Bridge.  If you don’t have the right Commercial leadership in place, are uncertain of your commercialization alternatives or, what it takes to commercialize successfully, give me a call and we’ll get your company on the path to commercial success.    Russ Belden Bridge: Founder & CEO russ@bridge1.net www.bridge1.net 415-307-0774 Danville, CA   At Bridge, we leverage our 36 years of biotech commercialization expertise from the early days at Genentech and 120 companies thereafter in providing the right level of commercial leadership at the right time. Our mission is making 1st time biotech CEO’s shine in the transition to a commercial company. #commercialization #PhaseIII #biotech #pharma #CEO #medicalaffairs

Crossing the chasm from Preclinical to Phase 1 Clinical Development for the 1st time at our emerging biotech company is a significant milestone! Aligning with the right Clinical Development, Regulatory, and CRO team is key. We are here to help you successfully navigate this transition with our all-inclusive support process called BridgeWorks. We offer a range of services, including Regulatory & Clinical Development, Corporate & Product Branding, Medical Affairs, Information Technology, and Talent Acquisition, in addition to our core leadership and commercialization roadmap. If you're at this critical juncture and exploring alternatives, let's connect for a detailed discussion on how we can assist you in your journey. For more information on how Bridge can support you in reaching your goals, reach out to Russ at russ@bridge1.net or 415-307-0774. Let’s collaborate to bring your biotech innovations to the market successfully. #biotech #pharma #branding #regulatoryaffairs #medicalaffairs #emergingbiotech #commercialization #commercializationroadmap #Phase1clinical #productlaunch #FirsttimeCEO #CBO #COO #CEO

I was looking at some of the up and coming biotech hubs in the U.S. According the an article in Drug Discovery & Development, Phoenix, Arizona is a rising star. "The bustling city is home to Phoenix Medical Quarter, a 100-acre hub set in the city’s midtown district, which aims to compete with top global medical research centers. The Mayo Clinic is also building its Discovery Oasis, a 120-acre medical and biotech research hub is strategically located between Mayo Clinic’s hospital campus and Loop 101 in north Phoenix." Some notable emerging biotechs in #Phoenix #Scottsdale include: Cellenion, CEO Holger Dr. Eickhoff, offer single cell sorting, isolation and dispensing, for cell line development and omics sample preparation. Any cell type, any sample type. CALVIRI, CEO Stephen Albert Johnston, is developing a diagnostic for the early detection of cancer in dogs and people, as well as off the shelf therapeutic and preventative cancer vaccines. Calviri is a spin-out of Arizona State University and headquartered in the Phoenix Bioscience Core. Systems Oncology, CEO Spyro Mousses, PhD., is modeling multi-dimensional disease mechanisms is critical to their ability to discover truly novel therapeutic opportunities. Understanding these mechanisms also allows them to resolve clinical heterogeneity in drug development. Taken together, this unique process empowers us to discover and develop the next generation of cancer therapies with unprecedented speed and precision. Journey Medical Corporation, CEO Lindsay Rosenwald, Journey is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The Journey team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Sonoran Biosciences, CEO Derek Overstreet, is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and prevention of surgical site infection. Need assistance commercializing your emerging biotech? Visit me at www.bridge1.net.

This article from Dr. Eric Heiden really speaks to me. The innate competitive drive that keeps an athlete motivated translates into their later careers. Dr. Heiden, who won five olympic gold medals in speed skating at the 1980 winter games and then went on to be an orthopedic surgeon, knows first hand what that drive feels like. I still have a significant case of nagging dissatisfaction and I don't know if that is a blessing or a curse at this point in my life, but that is what keeps me pushing forward to continually learn, take calculated risks and do better. #competitivedrive #Excellence #motivation #sports #business #career #olympics #athlete

Sharing an interesting article from PitchBook on the top cities for startups. According to the article, the top 10 cities for startups are San Francisco, New York, Beijing, Shanghai, Los Angeles, Boston, London, Shenzhen, Seoul, and Tokyo. If you're curious about the methodology behind these rankings, you can read more here: https://lnkd.in/gCxi4Qsy #startups #VC #finding #networking